Safety of primary immunization using inactivated SARS-CoV-2 vaccine (CoronaVac®) among population aged 3 years and older in a large-scale use: A multi-center open-label study in China.

ABSTRACT:

Objective

To evaluate the safety of primary immunization using CoronaVac® among population aged 3 years and above in a large-scale use.

Method

A multi-center open-label study was carried out in 11 provinces of China. Individuals aged 3 years and older who had no history of COVID-19 vaccination or had received only one dose of CoronaVac® were enrolled in this study. Adults and elderly with or without underlying medical conditions(UMCs) were also recruited. Eligible participants received one or two doses of CoronaVac® with an interval of 28 days. Demographic information, vaccination and the occurrence of adverse events were recorded by participants or guardians using data collection system designed for this study. All adverse events occurred within 6 months after the second do

SUBMITTER: Yang H 

PROVIDER: S-EPMC9837223 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature